Atrial fibrillation (AF) and flutter are risk factors for ischemic stroke or transient ischemic attacks (TIAs). 1 Considering that a significant risk reduction can be achieved by oral anticoagulants, identifying AF is clinically relevant. 2 However, a very high percentage of asymptomatic patients remain undiagnosed leading to a potential risk of thromboembolism. 3 The ideal method for the determination of AF/flutter in patients with stroke is not known. 4 A single electrocardiography (ECG) recording upon presentation with stroke was shown to detect a new diagnosis of AF in 2% to 3% of patients. 5 Holter monitoring has been used in several stroke units to identify potentially underdiagnosed AF. It has been suggested that every additional 24 hours of monitoring detects previously undiagnosed AF in an additional 2% to 4% of patients. 5 In a review investigating the methods to determine new AF/flutter, 24-to 72-hour Holter monitoring detected 4.6% of consecutive patients with ischemic stroke. 6 In another study, patients with stroke were investigated by 48-hour Holter monitoring or 21-day twice intermittent screening with a handheld ECG recorder. 4 They found a superiority of intermittent ECG recording method compared to 48-hour Holter monitoring (11.4%-2.8%, P ¼ .001). Accordingly, in another report, using transtelephonic ECG monitoring, paroxysmal AF episodes were detected in 9.2% of 98 consecutive patients following a recent stroke or TIA and a negative 24-hour Holter result. 7 Moreover, in 2 recent clinical trials, prolonged rhythm monitoring (in addition to Holter) was shown to be useful for the detection of AF after cryptogenic stroke. 8, 9 This suggests a substantial number of undiagnosed patients despite screening by 24-hour Holter monitoring.
Another topic of discussion has been that, besides the technique for screening AF, determination of patients at high risk of harboring asymptomatic paroxysmal AF can be another important point during the evaluation of patients with stroke. 5 Although the latest guidelines recommend cardiac monitoring for at least the first 24 hours following stroke, 10 the method for monitoring is not clear. In addition, the rationale for monitoring these patients does not only consists of determination of AF. It has also been emphasized that cardiac arrhythmias are potential complications of stroke and concurrent cardiac abnormalities may exist which constitute another reason for cardiac monitoring. 11 Hence, for how long and by which method do patients need cardiac monitoring following stroke? Considering the additional time, effort, and cost of these monitoring methods and possibly limited resources, clinical suspicion of patients with cardioembolic stroke may prove useful. However, a reliable clinical risk score to identify patients at high risk of AF is still lacking. 5 An important point may be that during selection for further cardiac monitoring in patients with stroke, patient age, life expectancy, and social status of the relations as well as compliance with anticoagulant treatment might constitute other criteria to be considered. On the other hand, there are also some concerns questioning the rationale of further investigations for paroxysmal AF in patients with stroke. In the European Atrial Fibrillation Trial (EAFT), the 1-year rate of recurrent stroke in patients with a history of TIA or stroke was 4% with anticoagulation, 10% with aspirin, and 12% with placebo. 2 Schaer et al 12 emphasized that the number needed to treat was 16 based on the secondary prevention EAFT trial. 2 They also mentioned the results 13 reporting a milder stroke reduction rate in patients with paroxysmal AF compared to permanent AF. In conclusion, they suggested determination of paroxysmal AF episodes not to be cost-effective. Hence, they declared that Holter monitoring only has a very limited effect on the clinical management of TIA or stroke. Nevertheless, there is still substantial support for routine Holter monitoring in patient following stroke. 14, 15 Of note, in patients with stroke or TIA with no other apparent cause, even prolonged rhythm monitoring (approximately 30 days) was recommended within 6 months of the event (class IIa; Level of Evidence C). 16 In conclusion, future randomized controlled studies are needed to clarify the arguments and produce a consensus for cardiac monitoring of patients following stroke for the determination of AF/atrial flutter. Considering the literature, conducting routine Holter monitor screening for all patients with TIA/stroke history and sinus rhythm may not be ideal. However, taking into consideration some other clinical, demographic, and social features of the patients and performing further cardiac monitoring in a specific subgroup with high risk of paroxysmal AF may add substantial benefit to their management.
